Hints and tips:
Related Special Reports
...The New York-based pharma group has acquired four companies — Arena, ReViral, Biohaven and Global Blood Therapeutics — that it expects will contribute about $10bn in revenues in 2030....
...If a transaction constitutes a concentration and has an EU dimension, it is always up to the companies to notify it.”...
...Emiliou “is of the view that member states may not request the commission to examine a concentration which does not have a community dimension, even where they have no competence to review such a concentration...
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
...Yet it seems to tread familiar Pixar paths: Dark, a gruff-voiced doofus voiced by Paul Walter Hauser, could have lumbered right out of Monsters, Inc while his cohorts rather resemble the personified emotions...
...CBOE’s BZX equities exchange features in the second chart because of just one stock, CBOE Global Markets Inc. None of this constitutes a scoop, we’ll be honest, but it’s a Friday....
...molnupiravir or Paxlovid will [still] be effective, now that most people have been either vaccinated or infected,” said Andy Hill, a senior visiting research fellow at Liverpool university’s pharmacology and therapeutics...
...to rescue Farfetch Regulators even out the antitrust score Global regulators had been on a losing streak lately, with back-to-back losses including Amgen’s $28bn takeover of fellow drugmaker Horizon Therapeutics...
...Monday’s acquisition by Novartis of Seattle-based biotech firm Chinook Therapeutics for up to $3.5bn is a case in point....
...Under the deadpan, Fassbender shows us just enough clammy panic to drag the role into two dimensions, even if his character is really only a mannequin for zany costume choices....
...The Regeneron chief executive has backed an attempt by US regulators to block Amgen’s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to...
...Andrew Hill, a senior visiting research fellow at Liverpool university’s pharmacology and therapeutics department, said the drug also had potential side effects for pregnant women....
...Massachusetts-based Luminopia, which creates therapeutic visual stimuli, raised $16mn in late June....
...regulators have warned that “rampant consolidation” in the pharmaceuticals industry is pushing up prices for patients as the Federal Trade Commission sued to block Amgen’s $28.3bn deal to acquire Horizon Therapeutics...
...Amgen has reached an agreement with the US antitrust regulator that allows the drugmaker to press ahead with its $28bn acquisition of Horizon Therapeutics....
...In addition, as recent research points to the effects of monetary policy on a growing list of economic outcomes, it seems challenging for monetary policy alone to balance all these dimensions....
...Khan has become such an antagonist for dealmakers and why they were rejoicing this month when Amgen reached a settlement with her agency, allowing the pharmaceutical company’s $28bn acquisition of Horizon Therapeutics...
...The Federal Trade Commission sued to block the biotechnology company Amgen’s $28.3bn deal to acquire Horizon Therapeutics, Italy is struggling to spend €200bn in EU Covid recovery funds, and Ukraine said...
...His comments came after the US Federal Trade Commission on Tuesday sued to block Amgen’s $28bn takeover of Horizon Therapeutics....
...Stratasys, 3D Systems, Nano Dimension and Desktop Metal rode a wave of investor interest in 3D printing, in which machines controlled by software build up products layer by layer....
...In December, biopharmaceutical firm Amgen announced the acquisition of biotech star Horizon Therapeutics for $116.50 per share or $28bn in aggregate....
...Amgen is close to a deal to acquire Horizon Therapeutics in a transaction worth as much as $20bn, according to sources familiar with the matter, as a sell-off in healthcare stocks creates attractive targets...
...Amgen has agreed to buy Horizon Therapeutics for $28.3bn, including debt, after the California-based biotech won a three-way race to secure a new pipeline of drugs for rare autoimmune and inflammatory diseases...
...The FTC attempted to block Amgen’s $28.3bn takeover of Horizon Therapeutics. Barriers to M&A are going to make it harder for pharma companies to replenish drug pipelines....
International Edition